Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT).
Medincell's Degree of Financial Leverage for the quarter that ended in Mar. 2026 was 0.42. The higher Degree of Financial Leverage, the more volatile earnings will be.
The industry rank for Medincell's Degree of Financial Leverage or its related term are showing as below:
MDCLF's Degree of Financial Leverage is ranked better than 72.09% of 1340
companies
in the Biotechnology industry
Industry Median: 0.95
vs MDCLF: 0.42
Medincell (OTCPK:MDCLF) Degree of Financial Leverage Explanation
Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.
The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.
Be Aware
The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.
Medincell Degree of Financial Leverage Related Terms
Medincell Degree of Financial Leverage Historical Data
* Premium members only.
The historical data trend for Medincell's Degree of Financial Leverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDCLF vs VRTX, REGN, ALNY: Degree of Financial Leverage Comparison
For the Biotechnology subindustry, Medincell's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medincell Degree of Financial Leverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medincell's Degree of Financial Leverage distribution charts can be found below:
* The bar in red indicates where Medincell's Degree of Financial Leverage falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
What does a Degree of Financial Leverage of 0.42 mean?
Medincell (MDCLF) has a Degree of Financial Leverage of 0.42 as of Mar. 2026. Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in EBIT. View historical data for Medincell and its competitors. According to the industry distribution chart, Medincell ranks #374 out of 1340 companies in the Biotechnology industry, placing it in the top 27.9%.
Is Medincell's Degree of Financial Leverage too high?
Medincell's current Degree of Financial Leverage is 0.42. The Biotechnology industry median Degree of Financial Leverage is 0.95. Medincell's value of 0.42 is 55.8% below this industry median. Based on the distribution chart, Medincell ranks #374 out of 1340 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medincell has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Medincell's Degree of Financial Leverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medincell ranks #374 out of 1340 companies for Degree of Financial Leverage. This puts Medincell in the upper half of its industry. The industry median Degree of Financial Leverage is 0.95. Medincell's value of 0.42 is 55.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Degree of Financial Leverage for a Biotechnology company?
The median Degree of Financial Leverage among Biotechnology companies is 0.95, based on 1,340 companies in the industry. Companies in the top quartile (top 25%) have a Degree of Financial Leverage significantly above this median, while those in the bottom quartile fall well below. However, Degree of Financial Leverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medincell's current Degree of Financial Leverage of 0.42 is 55.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Degree of Financial Leverage mean?
A high Degree of Financial Leverage can signal that a stock is expensive relative to its fundamentals. Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in EBIT. View historical data for Medincell and its competitors. For the Biotechnology industry, the median Degree of Financial Leverage is 0.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medincell's current Degree of Financial Leverage is 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Medincell (MDCLF) has a current Degree of Financial Leverage of 0.42. The stock's GF Value™ is $27.51, compared to a current price of $34.39 — trading 25% above its estimated fair value. The current Degree of Financial Leverage is 0.42 and 55.8% below the Biotechnology industry median of 0.95. Medincell's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Degree of Financial Leverage calculated?
Degree of Financial Leverage is calculated from a company's financial statements. For Medincell (MDCLF), the current Degree of Financial Leverage is 0.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medincell (MDCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Medincell stock appears to be overvalued.
The current stock price of $34.39 is trading 25% above its estimated GF Value™ of $27.51.
Key valuation signals for MDCLF:
Degree of Financial Leverage: 0.42
GF Value™: $27.51 vs. price of $34.39 (25% above fair value)
Industry Position: 55.8% below the Biotechnology median (#374 of 1340)
No single metric tells the full story. See the MDCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score
Get the complete analysis for MDCLF
Degree of Financial Leverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDCLF has been successfully added to your 
